Tectin™

The Company has chosen for its initial focus and regulatory approval one potential therapeutic indication from TTX - Tectin™. This leading drug candidate is designed for the analgesic market, specifically targeting inadequately controlled pain in patients with advanced cancer and was chosen as our lead product because of the need for a more natural drug which addresses chronic pain and offers less side effects with no addictive qualities.

WEX has completed a Canadian Phase IIa trial. The analysis showed Tectin™ to be meaningful as it relieved chronic pain in 71% of cancer pain patients. The Company has completed an interim analysis of its Canadian Phase IIb/III clinical trial. The results of the primary efficacy outcomes demonstrated unfavourable results leading to the recommendation to terminate the Canadian Phase IIb/III trial.  The Company will proceed to a detailed analysis of the results with the objective to identify a subset of patients who could potentially benefit from the drug. Results of this analysis will also serve to adjust the Tectin™ development plan whereby the cancer-related pain strategy could be modified as well as other types of pain could become new targets for future trials. Tectin™has been cleared for a severe non-malignant chronic pain trial in Canada.